IP Library Patent Application 18723131
Patent Application
App. No. 18/723,131

PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/723,131
Abstract

The invention comprises a process for the production of a linear P-linked oligonucleotide bearing an alkyl phosphonate group at 5′-terminus of the formula I wherein R 1 is a C 1-4 -alkyl group, R 2 is fluoro, hydroxyl or C 1-4 -alkoxy, X is sulfur or oxygen, the term Nucleobase stands for an optionally modified adenine, cytosine, guanine or uracil and the term oligo strand stands for the remaining P-linked oligo nucleotide strand, and wherein the oligo strand comprises at least one uracil nucleobase. The process is performed under conditions that the level of alkyl transfer impurities and the level of cyanoethyl (CNET) impurities in the linear P-linked oligonucleotide of formula I, is substantially reduced.

Claims (22)

1 . Process for the production of a linear P-linked oligonucleotide bearing an alkyl phosphonate group at the 5′-terminus of the formula

wherein R 1 is a C 1-4 -alkyl group, R 2 is fluoro, hydroxyl or C 1-4 -alkoxy, X is sulfur or oxygen, the term Nucleobase stands for an optionally modified adenine, cytosine, guanine or uracil and the term oligo strand stands for the remaining P-linked oligo nucleotide strand, and wherein the oligo strand comprises at least one uracil nucleobase, comprising the removal of the cyanoethyl group and one C 1-4 alkyl group from the oligonucleotide compound of formula II

wherein R 1 , R 2 , X, the term Nucleobase and the term oligo strand is as above, with a nucleophilic organic base in the presence of an organic solvent.

2 . Process of claim 1 , wherein R 1 is methyl.

3 . Process of claim 1 , wherein R 2 is fluoro or methoxy.

4 . Process of claim 1 , wherein the Nucleobase is adenine, cytosine, guanine, or uracil.

5 . Process of claim 1 , wherein the nucleophilic organic base has a nucleophilicity of higher than 15.

6 . Process of claim 1 , wherein the nucleophilic organic base has a pKa of the protonated organic base of less than 10.5.

7 . Process of claim 1 , wherein the nucleophilic organic base is a tertiary amine selected from morpholine, N,N-dimethylethylamine, N-methyl-pyrrolidine or 1,4-diazabicyclo[2.2.2]octane.

8 . Process of claim 1 , wherein the nucleophilic organic base is (1,4-diazabicyclo[2.2.2]octane) (DABCO).

9 . Process of claim 1 , wherein the organic solvent is selected from acetonitrile, pyridine and toluene or from mixtures thereof.

10 . Process of claim 1 , wherein the organic solvent is acetonitrile.

11 . Process of claim 1 , wherein the concentration of the nucleophilic organic base in the organic solvent is selected in the range of 5% (w) and 100% (w).

12 . Process of claim 1 , wherein the amount of the nucleophilic organic base is applied in a range of 1.5 CV to 30.0 CV and the flow rate is selected in the range of 0.1 CV/min to 2.0 CV/min.

13 . Process of claim 1 , wherein the process is performed under conditions that the level of alkyl transfer impurities, expressed as “sum of N+alkyl impurities”, in the linear P-linked oligonucleotide of formula I, is below 4.0%.

14 . Process of claim 1 , wherein the process is performed under conditions that the level cyanoethyl (CNET) impurities, expressed as “sum of CNET impurities”, in the linear P-linked oligonucleotide of formula I, is below 2.0%.

15 . Process of claim 5 , wherein the nucleophilic organic base as a nucleophilicity of between 16 and 25.

16 . Process of claim 6 , wherein the nucleophilic organic base has a pKa of the protonated organic base of between 8 and 10.5.

17 . Process of claim 11 , wherein the concentration of the nucleophilic organic base in the organic solvent is selected in the range of 15% (w) to 25% (w).

18 . Process of claim 12 , wherein the amount of the nucleophilic organic base is applied in a range of 1.5 CV to 30.0 CV and the flow rate is selected in the range of 0.1 CV/min to 0.5 CV/min.

19 . Process of claim 13 , wherein the process is performed under conditions that the level of alkyl transfer impurities, expressed as “sum of N+alkyl impurities”, in the linear P-linked oligonucleotide of formula I, is below 0.5%.

20 . Process of claim 14 , wherein the process is performed under conditions that the level cyanoethyl (CNET) impurities, expressed as “sum of CNET impurities”, in the linear P-linked oligonucleotide of formula I, is below 0.5%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2025
From: DICERNA PHARMACEUTICALS, INC.
To: NOVO NORDISK A/S
Reel/Frame 070837/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: KOMISARSKI, MAREK STANISLAW; MUELLER, PASCAL; OLBRICH, MARTIN; ROMANO, JOHANNA; SCHUSTER, ANDREAS
To: DICERNA PHARMACEUTICALS, INC.
Reel/Frame 068430/0001 →